Thanks to Alain Samoun for the following post:
A private MD in France Dr Sabine Paliard-Franco has started a new drug treatment on her COVID19 patients with great success. Her very sick patients presented all the respiratory symptoms of the covid19 to the point that, at the beginning, she thoughts that they would have to be sent to hospital and, for some, to die there. Nevertheless she tried on them a very well known type of anti-inflammatory and antibacterial drugs called MACROLIDE Already used in other respiratory viral infections. The results were spectacular in 24 to 72 hours all patients lost all their viral sickness symptoms and most were cured. She has published her work to help others doctors in France.
UPDATE: A kind reader has provided an English translation of the above document, can be read here:French doctor translation
Note that the drugs are well known and very cheap. The treatment of Dr Paliard-Franco can be given at home and does not need hospitalization.
Here is the abstract on “Macrolide Therapy in Respiratory Viral Infections”
A paper that, it seems, many did not read or forgotten:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3375106/ by Jin-Young Min and Yong Ju Jang
College of Medicine, 388-1 Pungnap-2dong, Songpa-gu, Seoul
Macrolides have received considerable attention for their anti-inflammatory and immunomodulatory actions beyond the antibacterial effect. These two properties may ensure some efficacy in a wide spectrum of respiratory viral infections. We aimed to summarize the properties of macrolides and their efficacy in a range of respiratory viral infection. Methods. A search of electronic journal articles through PubMed was performed using combinations of the following keywords including macrolides and respiratory viral infection. Results. Both in vitro and in vivo studies have provided evidence of their efficacy in respiratory viral infections including rhinovirus (RV), respiratory syncytial virus (RSV), and influenza virus. Much data showed that macrolides reduced viral titers of RV ICAM-1, which is the receptor for RV, and RV infection-induced cytokines including IL-1β, IL-6, IL-8, and TNF-α. Macrolides also reduced the release of proinflammatory cytokines which were induced by RSV infection, viral titers, RNA of RSV replication, and the susceptibility to RSV infection partly through the reduced expression of activated RhoA which is an RSV receptor. Similar effects of macrolides on the influenza virus infection and augmentation of the IL-12 by macrolides which is essential in reducing virus yield were revealed. Conclusion. This paper provides an overview on the properties of macrolides and their efficacy in various respiratory diseases.-inflamation and antibacterial